Tag : Myeloma

Pharma / Biotech

Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.

Newsemia
Related Articles Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide,...
Pharma / Biotech

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.

Newsemia
Related Articles Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020 Feb...
Latest News

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Newsemia
Moreau, P; Dimopoulos, MA; Yong, K; Mikhael, J; Risse, M-L; Asset, G; Martin, T; (2020) Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple...
Biology

Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152-3p [Research Article]

Newsemia
Multiple myeloma (MM) accounts for over twenty percent of hematological cancer-related death worldwide. Long noncoding RNA (lncRNA) H19 is associated with multiple tumorigenesis and is...
Gastroenterology

Researchers discover a way to move precision immunotherapy forward for multiple myeloma

Newsemia
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy...
Latest News

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma

Newsemia
BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and...
Neurology

Phase 2 clinical trial of CAR T-cell therapy starts at Atlantic Health System

Newsemia
Atlantic Health System is treating patients in a new Phase 2 clinical trial of CAR T-cell therapy at Morristown Medical Center. A select number of...
Latest News

Exposure to 9/11 WTC dust associated with increased risk of heart disease in NYC firefighters

Newsemia
A new study of New York City firefighters has found that exposure to 9/11 World Trade Center dust is associated with a significantly increased long-term...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy